Regeneron’s linvoseltamab gets FDA priority review in R/R multiple myeloma
Regeneron Pharmaceuticals said that the US Food and Drug Administration (FDA) has accepted its biologics licence application (BLA) for priority review of linvoseltamab in the treatment of certain